Protein Summary
Component of the HBO1 complex which has a histone H4-specific acetyltransferase activity, a reduced activity toward histone H3 and is responsible for the bulk of histone H4 acetylation in vivo. Transcriptional coactivator, it may also promote acetylation of nucleosomal histone H4 by KAT5. Promotes apoptosis. May act as a renal tumor suppressor. Negatively regulates canonical Wnt signaling; at least in part, cooperates with NPHP4 in this function.
- ENST00000226319
- ENSP00000226319
- ENSG00000077684
- ENST00000413543
- ENSP00000404211
- ENST00000452328
- ENSP00000388015
- ENST00000511647
- ENSP00000423737
- ENST00000512960
- ENSP00000425730
- ENST00000610919
- ENSP00000483219
- ENST00000611140
- ENSP00000482212
- KIAA1807
- PHF17
- PHF17
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
kinase perturbation | 1 | ||
transcription factor perturbation | 0.99 | ||
microRNA | 0.96 | ||
transcription factor binding site profile | 0.93 | ||
transcription factor | 0.87 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 20.17 (req: < 5)
Gene RIFs: 17 (req: <= 3)
Antibodies: 176 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 20.17 (req: >= 5)
Gene RIFs: 17 (req: > 3)
Antibodies: 176 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 10
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0